Debajit Sen

Debajit Sen

Auto-generated profile, based on publicly available information

Debajit Sen

Department of Rheumatology University College London Hospital, London, UK

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2017 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
RCRan A Cai
Ran A Cai
DBDominik Beste
Dominik Beste
HCHema Chaplin
Hema Chaplin
SVSocrates Varakliotis
Socrates Varakliotis
LSLinda Suffield
Linda Suffield
DEDespina Eleftheriou
Despina Eleftheriou
Flare-ups in juvenile idiopathic arthritis (JIA) are characterized by joint pain and swelling and often accompanied with fatigue, negative emotions, and reduced participation in activities. To minimize the impact of JIA on the physical and psychosocial development and well-being of young people (YP), it is essential to regularly monitor disease activity and side effects, as well as to support self-management such as adherence to treatment plans and engagement in general health-promoting behaviors. Smartphone technology has the potential to engage YP with their health care through convenient self-monitoring and easy access to information. In addition, having a more accurate summary of self-reported fluctuations in symptoms, behaviors, and psychosocial problems can help both YP and health care professionals (HCPs) better understand the patient's condition, identify barriers to self-management, and assess treatment effectiveness and additional health care needs. No comprehensive smartphone app has yet been developed in collaboration with YP with JIA, their parents, and HCPs involved in their care. The objective of this study was to design, develop, and evaluate the acceptability and usability of JIApp, a self-management smartphone app system for YP with JIA and HCPs. We used a qualitative, user-centered design approach involving YP, parents, and HCPs from the rheumatology team. The study was conducted in three phases: (1) phase I focused on developing consensus on the features, content, and design of the app; (2) phase II was used for further refining and evaluating the app prototype; and (3) phase III focused on usability testing of the app. The interview transcripts were analyzed using qualitative content analysis. A total of 29 YP (aged 10-23, median age 17) with JIA, 7 parents, and 21 HCPs were interviewed. Major themes identified as the ones that helped inform app development in phase I were: (1) remote monitoring of symptoms, well-being, and activities; (2) treatment adherence; and (3) education and support. During phase II, three more themes emerged that informed further refinement of the app prototype. These included (4) adapting a reward system to motivate end users for using the app; (5) design of the app interface; and (6) clinical practice integration. The usability testing during phase III demonstrated high rates of overall satisfaction and further affirmed the content validity of the app. We present the development and evaluation of a smartphone app to encourage self-management and engagement with health care for YP with JIA. The app was found to have high levels of acceptability and usability among YP and HCPs and has the potential to improve health care and outcomes for this age group. Future feasibility testing in a prospective study will firmly establish the reliability, efficacy, and cost-effectiveness of such an app intervention for patients with arthritis.

1 July 2002 in Hospital Medicine
Verified
Journal Article
Closed access
DSD Sen
D Sen
SCS Chhaya
S Chhaya
VMVh Morris
Vh Morris
Carpal tunnel syndrome is the most commonly diagnosed entrapment neuropathy. This review looks at the current body of evidence to help determine optimal practice for the diagnosis and management of this condition.

1 June 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
VCV. Choida
V. Choida
AMAnastasia-Vasiliki Madenidou
Anastasia-Vasiliki Madenidou
DSD. Sen
D. Sen
MHM. Hall-Craggs
M. Hall-Craggs
CCCoziana Ciurtin
Coziana Ciurtin
Background: Whole body MRI (WBMRI) is an imaging technique that allows the assessment of the spine and peripheral joints in patients with inflammatory arthritis (IA) in a single examination. Depending on the protocol, it can potentially identify synovitis, enthesitis, spondyloarthritis and chronic structural changes. Objectives: To evaluate the performance of WBMRI in patients with IA for detecting inflammation compared with clinical assessments and to show changes in response to treatment. Methods: We conducted a systematic search of the electronic databases MEDLINE, EMBASE and Cochrane Library. Two authors selected independently the eligible studies, extracted the predefined data and assessed the quality using the QUADAS2 tool. Studies that reported a)disease activity scores, b)patient or physician reported outcomes or c)results from other imaging tests in IA patients who underwent WBMRI were included. Results: Fourteen studies out of 471 met our inclusion criteria. The majority of the studies were performed in Spondyloarthritis [SpA] (n=9), followed by Rheumatoid Arthritis [RA] (n=4) and Psoriatic Arthritis [PsA] patients (n=3). Nine studies provided clinical and MRI outcome measures. There was great heterogeneity in the quality of studies, disease specific outcomes reported and methodology used to compare with MRI findings. One study documented low correlation between 28 swollen/tender joint count and MRI bone marrow oedema (BME)/synovitis in RA patients, whereas another reported that 31% of MRI negative joints (other than hand joints) exhibited tenderness. In PsA, one study demonstrated correlation between 28 swollen joint count and BME (r=0.54,p=0.03). Superiority of WBMRI in the detection of synovitis and enthesitis over clinical examination was documented in two studies with SpA patients. A third study in SpA showed a ranging agreement of 49 to 100% between clinical and WBMRI enthesitis. Treatment response to biologics was assessed by WBMRI in 7 studies (5 in SpA, 2 in RA). In RA, one study showed numerical (but not statistically significant) reduction of WBMRI joint count at week 16 and 52 of Adalimumab treatment, whereas the reduction was statistically significant for the subset of patients achieving good EULAR response at week 16. The other study demonstrated a reduction in WBMRI synovitis and bone oedema scores after 1 year of anti-TNF or Tocilizumab treatment (median DAS28 score decreased from 5.1 to 2.1). A multicentre open label study reported a reduction in the number of MRI enthesitis lesions, spinal and sacroiliac joint scores at week 48, year 2 and 3 of Etanercept treatment in SpA patients. The mean BASDAI score decreased from 5.4 at baseline to 1.5 at year 2 and 2.2 at year 3. Improvement in WBMRI scores in SpA was also documented in one Adalimumab and one further Etanercept study. Conclusion: There was a variable level of correlation between clinical and WBMRI outcome measures across the included studies. The clinical significance of inflammation detected by WBMRI in some studies remains unclear. Many of the devised WBMRI scores appear to decrease after biologic treatment. Further studies are needed to determine the accuracy of WBMRI in detecting inflammation and its potential utility for clinical practice. Disclosure of Interests: Varvara Choida: None declared, Anastasia-Vasiliki Madenidou: None declared, Debajit Sen: None declared, Margaret Hall-Craggs: None declared, Coziana Ciurtin Grant/research support from: Pfizer, Consultant of: Roche, Modern Biosciences

4 March 2021
Verified
Conference Paper
Open access
SBSwarnava Biswas
Swarnava Biswas
DSDebajit Sen
Debajit Sen
RMRohit Mahajan
Rohit Mahajan
MMMoumita Mukherjee
Moumita Mukherjee
The nCOVID-19 has wreaked our normal lifestyle and has forced us to adopt the protocols under the new normal regime. The conventional diagnostic approach is expected to change in the process as well. Our research group is proposing an aid to such diagnostic approach. The group has proposed in this article the power of using two such diagnostic measures that has been the pivot for many diagnoses to the doctors. The art of using natural language processing based symptomatic measure in combination with a machine learning based approach based on medical vitals can collectively reduce the error percentage of detection. The approach proposed in this article is a first of its kind and the authors have achieved acceptable results on the accuracy front. The other reason of proposing such a technique is the way a fusion algorithm can arrive at the right results from two parallel algorithms doing the same task. Another objective of the group was to provide a valuable opinion to the doctor in form of such an architecture. The proposed architecture can be used at any point of care facilities without any requirement of escalation of the existing amenities.

14 April 2026 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
AAAmaani Ahmad
Amaani Ahmad
SOSameera Oruganti
Sameera Oruganti
ZLZahra Ladan
Zahra Ladan
NZNicole Y. Zhang
Nicole Y. Zhang
LWLouise Willoughby
Louise Willoughby
DSDebajit Sen
Debajit Sen
Introduction: Chronic inflammation associated with ageing contributes to sarcopenia-related risk of falls and multimorbidity. The SARC-F questionnaire, based on strength, ambulation, rising from a chair, climbing stairs and falling, and MSRA (mini sarcopenia risk assessment) are validated tools to identify sarcopenia in elderly people. Here, we investigated whether SARC-F and MSRA questionnaires capture higher rates of self-reported functional difficulties and falls in young individuals living with juvenile idiopathic arthritis (JIA). Methods: JIA patients and healthy participants were invited to complete an online survey including the SARC-F, MSRA-5, and MSRA-7 questionnaires. Additional questions explored their nutrition and exercise habits. Results: We invited 101 healthy participants and 41 patients with JIA. Of the 41 JIA respondents, the median age was 23 years and 25 (61%) were female. According to the SARC-F, MSRA-5, and MSRA-7 questionnaires, 20%, 47%, and 33% screened positive according to the respective threshold criteria. Around 27% of JIA patients reported at least one fall in the past year compared to around 33% of healthy participants. However, 20% of JIA participants reported more than four falls in the past year in contrast to 4% of healthy participants. Furthermore, 44% of JIA participants reported difficulty climbing stairs and 17% reported limited ability to walk one kilometer. Conclusions: SARC-F identified a higher proportion of young adults with JIA reporting functional difficulties and recurrent falls compared with healthy controls. MSRA-5 showed differences in some risk-factor domains. However, without validation against objective measures of muscle mass, strength, or performance, these questionnaires primarily reflect multifactorial JIA-related musculoskeletal impairment rather than sarcopenia per se. Further studies with gold-standard sarcopenia assessments are needed.

25 April 2026 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
MCMikhail Carrim
Mikhail Carrim
MSMuhammad R. A. Shipa
Muhammad R. A. Shipa
ABAicha Bouraoui
Aicha Bouraoui
TAToka Alsulaim
Toka Alsulaim
CFCorinne Fisher
Corinne Fisher
DSDebajit Sen
Debajit Sen
Background: Secondary drug failure to adalimumab remains a significant challenge in managing Juvenile Idiopathic Arthritis (JIA), with anti-adalimumab antibodies (ADA_ab) implicated as a potential mechanism. This study examines the relationship between ADA_ab formation and loss of response (LOR). Findings: In this retrospective, longitudinal study, a combination of conventional statistical methods and machine-learning algorithms were employed to investigate the association of adalimumab drug levels (ADA_drug) and ADA_ab, alongside clinical variables, on LOR among JIA patients treated between December 2016 and May 2024. LOR was defined as active disease. Among 184 patients, ADA_ab and ADA_drug emerged as the strongest predictors of LOR in random-forest analysis. In multiple logistic regression, higher ADA_ab levels were independently associated with increased risk of LOR (OR 1.18, 95% CI 1.08–1.29, p = 0.0003), while higher ADA_drug levels were associated with reduced risk (OR 0.81, 95% CI 0.68–0.95, p = 0.0103). An ADA_ab threshold of 69 AU/mL was associated with an eightfold increase in LOR (OR 8.04, 95% CI 2.8–26.1, p = 0.0002). Patients with high ADA_ab and undetectable ADA_drug had the highest risk of LOR (OR 28.24, 95% CI 7.11–111.63, p = 0.0001). Kaplan–Meier analysis demonstrated that 71% of patients with elevated ADA_ab experienced LOR within 12 months Conclusion: High ADA_ab levels are a significant predictor of LOR in JIA patients treated with adalimumab, particularly when coupled with low drug levels. We also report clinically meaningful one-year LOR rates. These findings support the use of therapeutic drug monitoring, which may help optimise treatment and improve long-term disease control.